Skip to main content

Table 2 Results

From: Efficacy of platelet-rich plasma and plasma for symptomatic treatment of knee osteoarthritis: a double-blinded placebo-controlled randomized clinical trial

Outcomes

Groups

Baseline

Week 6

Week 12

Week 24

p-value intergroup*

VAS 0-10 cm for overall pain, mean (SD)

PRP

6.1 (1.6)

3.7 (2.4)

2.0 (1.4)

3.2 (2.5)

0.483

Plasma

5.9 (1.4)

3.7 (2.5)

3.2 (2.8)

3.5 (2.4)

Placebo

6.6 (1.4)

3.5 (2.1)

3.9 (2.7)

3.1 (2.6)

VAS for overall pain (change from baseline), mean (SD)

PRP

-

-2.4 (2.7)

-4.1 (1.6)

-2.9 (2.5)

0.499

Plasma

-

-2.2 (2.3)

-2.7 (3.0)

-2.4 (2.5)

 

Placebo

-

-3.1 (2.5)

-2.7 (3.2)

-3.5 (3.3)

 

VAS for overall pain, % of improvement, mean (SD)

PRP

-

-36.5 (39.7)

-67.0 (23.0)

-46.4 (41.3)

nsa

Plasma

-

-36.2 (39.8)

-43.5 (55.6)

-38.0 (50.4)

 

Placebo

-

-43.4 (46.5)

-35.8 (52.5)

-46.5 (54.3)

 

VAS 0-10 cm for pain at rest, mean (SD)

PRP

2.5 (2.3)

1.2 (1.6)

0.6 (0.8)

1.6 (2.2)

0.216

Plasma

1.5 (1.9)

0.8 (1.1)

0.6 (0.7)

0.9 (0.9)

Placebo

1.9 (1.9)

1.6 (2.0)

1.0 (1.2)

1.4 (2.3)

VAS 0-10 cm for pain at movement, mean (SD)

PRP

6.8 (2.1)

4.7 (2.8)

3.7 (2.3)

3.7 (2.8)

0.928

Plasma

6.8 (2.1)

4.5 (3.1)

3.9 (3.1)

4.0 (2.7)

Placebo

6.8 (2.0)

4.2 (2.2)

3.9 (2.9)

3.5 (2.6)

PhGA 0-10 cm, mean (SD)

PRP

4.6 (1.9)

3.3 (2.0)

2.3 (1.4)

3.0 (2.0)

0.634

Plasma

4.6 (1.5)

3.1 (2.0)

2.9 (2.1)

3.1 (1.8)

Placebo

4.1 (1.7)

2.7 (1.8)

2.5 (1.5)

2.7 (2.0)

PGA (0-100%), mean (SD)

PRP

-

48.0 (29.9)

67.3 (21.6)

56.3 (29.2)

0.639

Plasma

-

59.0 (25.3)

63.2 (24.5)

67.7 (18.8)

 

Placebo

-

59.0 (27.0)

57.7 (31.1)

66.7 (25.4)

 

Likert for global improvementb, %

PRP

-

0 – 10%

0 – 0%

0 – 5%

nsc

1 – 15%

1 – 5%

1 – 20%

2 – 25%

2 – 20%

2 – 15%

3 – 45%

3 – 60%

3 – 35%

4 – 5%

4 – 15%

4 – 25%

 

Plasma

-

0 – 5%

0 – 0%

0 – 0%

 

1 – 10%

1 – 15%

1 – 5%

2 – 35%

2 – 20%

2 – 40%

3 – 45%

3 – 50%

3 – 35%

4 – 5%

4 – 15%

4 – 20%

 

Placebo

-

0 – 10%

0 – 14%

0 – 5%

 

1 – 10%

1 – 10%

1 – 14%

2 – 33%

2 – 19%

2 – 5%

3 – 38%

3 – 48%

3 – 67%

4 – 10%

4 – 10%

4 – 10%

WOMAC Pain 0-20, mean (SD)

PRP

10.7 (3.2)

7.9 (3.7)

5.6 (2.6)

6.6 (3.5)

0.561

Plasma

9.2 (2.5)

6.8 (3.6)

6.1 (3.9)

6.5 (3.6)

Placebo

11.0 (3.1)

7.4 (3.5)

7.1 (2.8)

6.2 (2.3)

WOMAC stiffness 0-8, mean (SD)

PRP

4.4 (1.7)

2.8 (1.7)

2.1 (1.0)

2.7 (1.6)

0.713

Plasma

4.0 (1.4)

2.9 (1.7)

2.6 (1.9)

2.5 (1.7)

Placebo

4.3 (1.8)

2.8 (1.6)

3.0 (1.5)

2.8 (1.5)

WOMAC function 0-68, mean (SD)

PRP

37.9 (11.6)

25.8 (12.0)

21.2 (9.8)

23.5 (14.3)

0.847

Plasma

33.5 (11.2)

25.4 (13.9)

20.9 (14.6)

24.2 (15.5)

Placebo

37.0 (12.0)

26.6 (12.5)

24.7 (10.0)

22.6 (11.0)

WOMAC Total 0-96, mean (SD)

PRP

52.9 (15.5)

36.4 (16.7)

28.9 (12.6)

32.7 (18.9)

0.787

Plasma

46.7 (14.3)

35.0 (18.5)

29.6 (19.9)

33.2 (20.3)

Placebo

52.3 (15.9)

36.9 (17.1)

34.9 (13.5)

31.6 (14.4)

KOOS Symptoms 0-100, mean (SD)

PRP

46.1 (21.0)

67.0 (19.0)

71.4 (13.2)

63.9 (21.2)

0.442

Plasma

56.1 (21.6)

66.3 (18.1)

69.4 (20.0)

66.0 (23.6)

Placebo

45.4 (15.9)

63.6 (15.8)

59.9 (17.1)

65.3 (17.4)

KOOS Pain 0-100, mean (SD)

PRP

42.9 (15.3)

63.9 (18.7)

67.6 (12.5)

62.4 (20.1)

0.434

Plasma

40.8 (17.5)

61.9 (19.3)

67.5 (21.9)

66.1 (21.0)

Placebo

40.7 (14.6)

58.7 (13.9)

59.4 (16.2)

66.1 (16.7)

KOOS ADL 0-100, mean (SD)

PRP

44.4 (15.3)

64.3 (18.3)

68.3 (17.0)

64.0 (20.7)

0.607

Plasma

51.8 (18.6)

65.9 (19.0)

70.4 (21.8)

67.7 (19.7)

Placebo

45.4 (16.2)

62.0 (16.0)

63.3 (15.4)

68.6 (16.7)

KOOS Sport/Recreation 0-100, mean (SD)

PRP

12.8 (10.9)

27.8 (19.0)

35.5 (21.0)

32.8 (21.1)

0.031d

Plasma

29.8 (21.0)

38.8 (27.8)

51.7 (30.3)

46.0 (25.2)

Placebo

17.4 (12.2)

33.8 (20.7)

35.7 (16.4)

40.7 (21.6)

KOOS QOL 0-100, mean (SD)

PRP

18.1 (13.9)

33.1 (21.4)

48.1 (22.0)

39.1 (22.4)

0.336

Plasma

29.5 (16.4)

42.3 (25.4)

51.5 (27.5)

45.2 (22.7)

Placebo

25.0 (15.3)

39.0 (20.2)

43.2 (16.9)

50.6 (22.7)

OMERACT-OARSI Criteria, %

PRP

-

75%

95%

80%

nse

Plasma

-

70%

85%

80%

 

Placebo

-

81%

76%

86%

 

TUGT (s), mean (SD)

PRP

13.6 (2.8)

13.0 (3.2)

11.6 (1.6)

11.5 (1.3)

0.866

Plasma

13.8 (3.1)

12.1 (2.7)

12.2 (3.0)

12.2 (3.0)

Placebo

13.6 (3.0)

12.3 (2.7)

11.4 (2.0)

11.4 (2.4)

  1. * This p-value represents difference between groups; there was a statistically significant difference intragroup for all baseline parameters in relation to 6, 12 and 24 weeks
  2. a P-value intergroup week 6: p = 0.823; week 12: p = 0.162; week 24: p = 0.814
  3. b 0 - no improvement; 1 - mild improvement; 2 - moderate improvement; 3 - good improvement; 4 - excellent improvement
  4. c P-value intergroup week 6: p = 0.986; week 12: p = 0.712; week 24: p = 0.076. There was a significant difference in the PRP group between weeks 6 and 12 (p = 0.003) suggesting better responses in week 12
  5. d The difference occurred due to difference between groups PRP and plasma (p = 0.03) from week 6 to week 12 (p = 0.005)
  6. e P-value intergroup week 6: p = 0.767; week 12: p = 0.268; week 24: p = 0.872
  7. Abbreviations: VAS visual analogue scale 0-10 cm, SD standard deviation; ns: no statistical significance, PhGA physician global assessment 0-10 cm, PGA participant’s global assessment for improvement, WOMAC Western Ontario McMaster Universities Osteoarthritis Index, KOOS Knee Injury and Osteoarthritis Outcome Score, ADL function in daily living, QOL quality of life, TUGT timed up and go test
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us